Verici Dx completes WRAP Retail Offer and raises additional gross proceeds

VRCI

Verici Dx Plc (LON:VRCI) has confirmed the result of its WRAP Retail Offer at the issue price of 0.35 pence per share, following the announcements made on 8 June 2026. The Company has raised aggregate gross proceeds of approximately £0.19 million pursuant to the WRAP Retail Offer in addition to the previously announced Placing. Accordingly, the Company will issue a total of 53,345,832 WRAP Retail Offer Shares.

In total, the Placing and the WRAP Retail Offer has raised gross proceeds of approximately £2.6 million for the Company, via the Placing of 700,000,000 Placing Shares and the 53,345,832 WRAP Retail Offer Shares.

For the avoidance of doubt, the WRAP Retail Offer is not part of the Placing. The issue of the WRAP Retail Offer Shares is conditional upon:

  • the passing of certain resolutions to be put to shareholders of Verici Dx plc at a General Meeting, which is expected to be held at Shoosmiths LLP’s London office at 1 Bow Churchyard, London EC4M 9DQ at 11.30 a.m. on 22 June 2026; and
  • the new Ordinary Shares being admitted to trading on AIM.

Terms used but not defined in this announcement have the same meaning as set out in the Company’s announcement released at 7am on 8 June 2026.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Verici Dx provides PTRA testing for phase 2 organ transplant clinical trial

Verici Dx has secured an order from Asahi Kasei Therapeutics to provide blood-based biomarker testing, including its PTRA assay,...

Verici DX reports stronger test adoption and progress towards break-even

Verici DX reported higher test revenue, faster customer adoption and increased orders, while maintaining its target of reaching cash...

Verici Dx targets cash flow breakeven by end of 2027 as US sales expand

Verici Dx is expanding its US sales operation following an £8.75 million fundraising, targeting cash flow breakeven by the...

Kidney Research UK funds new kidney-on-a-chip model to investigate transplant rejection

Kidney Research UK has awarded £110,000 to develop a kidney-on-a-chip model that could help researchers understand transplant rejection, identify...

Verici Dx targets cash-flow breakeven by end of 2027 as Tutivia sales grow

Verici Dx reports 52% year-on-year growth in third-quarter Tutivia orders and targets cash-flow breakeven by the end of 2027....

Verici Dx raises £8.75m through share placing as 2.69bn new shares join AIM

Verici Dx has completed its £8.75m fundraising, with 2.69 billion new ordinary shares admitted to trading on AIM. CEO...

Search